Research Roundup


20191453 - idea concept with light bulbs and energy save bulb green background

Debbie Rigby takes a look at the latest in research news

Inhaled budesonide in the treatment of early COVID-19 (STOIC)

A randomised controlled trial (Steroids in COVID-19; STOIC) of inhaled budesonide, compared with usual care, in adults within 7 days of the onset of mild COVID-19 symptoms has shown that early administration of inhaled budesonide reduces the likelihood of needing urgent medical care and reduced time to recovery after early COVID-19. The number needed to treat with inhaled budesonide to reduce COVID-19 deterioration was eight.

Lancet Respiratory Medicine, published 9 April 2021.

 

Non-alcoholic fatty liver disease

Non-alcoholic fatty liver disease (NAFLD) is a leading cause of cirrhosis and hepatocellular carcinoma. NAFLD has a bidirectional association with components of the metabolic syndrome, and type 2 diabetes increases the risk of cirrhosis and related complications. There is currently no approved therapy for NAFLD. Healthy lifestyle and weight reduction remain crucial to the prevention and treatment of NAFLD.

Lancet, published 21 April 2021.

 

Step-by-step model for a brief behavioural treatment for insomnia

The aim of this article is to present a step-by-step approach for Australian general practitioners to administer brief behavioural therapy for insomnia. The four ‘rules’ of brief behavioural therapy for insomnia include bedtime restriction therapy; get up at the same time of day every day of the week, no matter how poorly you slept the night before; do not go to bed unless sleepy; and stimulus control therapy.

Australian Journal of General Practice 2021;50(5):287-93.

 

Off-label medicine use: Ethics, practice and future directions

Medicine use is considered off-label when used for an indication, at a dose, via a route of administration or in a patient group not included in the approved product information. Not all off-label medicine use is inappropriate, and there are conditions for which an off-label medicine is the treatment of choice. This article suggests patients should be informed that their treatment is off-label and be engaged in a full and open discussion regarding benefits and risks.

Australian Journal of General Practice 2021;50(5):329-31.

 

Previous Here's what you said
Next Making an impact

NOTICE: It can sometimes take awhile for comment submissions to go through, please be patient.

No Comment

Leave a reply